Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

For instance, it licensed CureVac ’s cancer vaccine CV9202 in 2014, formed a collaboration with Philogen seeking immunotherapies for acute myeloid leukaemia in 2015, and partnered an oncolytic virus therapy developed

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... CureVac is also eligible to

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    225. CureVac/ Sanofi Pasteur. Exercise of option, licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    CureVac’ s CEO appointed to EC High Level Group. Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes. ... Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    CureVac appoints chief financial officer. Pierre Kemula joins the mRNA company’ s management board. ... Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics